Silence Therapeutics PLC
SLN5.780USD
-0.390-6.32%
交易中 （美东）报价延迟15分钟
818.97M总市值
亏损市盈率 TTM
关于 Silence Therapeutics PLC 公司
Silence Therapeutics plc 是一家总部位于英国的生物技术公司。该公司利用人体的天然 RNA 干扰 (RNAi) 机制来抑制特定靶基因的表达，从而开发药物。该公司的 mRNAi GOLD（GalNAc 寡核苷酸发现）平台可用于创建 siRNA（短干扰 RNA），精确靶向和沉默肝脏中的疾病相关基因。其全资拥有的候选产品包括 zerlasiran (SLN360)，旨在满足降低出生时高脂蛋白 (a) 水平人群心血管风险这一普遍存在的未满足医疗需求，以及 SLN124，旨在治疗血液病。该公司还与阿斯利康、Mallinckrodt Pharmaceuticals 和 Hansoh Pharma 等公司保持持续的研发合作。这些合作总共代表了多达 16 个管道项目。其其他在研产品包括SLN-HAN-1和SLN-HAN-2。
公司简介
公司代码SLN
公司名称Silence Therapeutics PLC
上市日期Jan 05, 2010
CEOMr. Craig A. Tooman
员工数量116
证券类型Depository Receipt
年结日Jan 05
公司地址72 Hammersmith Road
城市LONDON
上市交易所NASDAQ Global Market Consolidated
国家United Kingdom
邮编W14 8TH
电话442034576900
网址https://www.silence-therapeutics.com/
公司代码SLN
上市日期Jan 05, 2010
CEOMr. Craig A. Tooman
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Timothy (Tim) McInerney
Mr. Timothy (Tim) McInerney
Independent Director
Independent Director
--
--
Mr. Craig A. Tooman
Mr. Craig A. Tooman
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Dr. Steven J. Romano, M.D.
Dr. Steven J. Romano, M.D.
Executive Vice President, Chief of Research and Development Officer
Executive Vice President, Chief of Research and Development Officer
--
--
Ms. Rhonda Heliums
Ms. Rhonda Heliums
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Mr. Iain Gladstone Ross
Mr. Iain Gladstone Ross
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. David Jakob (Dave) Lemus, CPA
Mr. David Jakob (Dave) Lemus, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Gem Hopkins
Ms. Gem Hopkins
Head of IR and Corporate Communications
Head of IR and Corporate Communications
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Timothy (Tim) McInerney
Mr. Timothy (Tim) McInerney
Independent Director
Independent Director
--
--
Mr. Craig A. Tooman
Mr. Craig A. Tooman
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Dr. Steven J. Romano, M.D.
Dr. Steven J. Romano, M.D.
Executive Vice President, Chief of Research and Development Officer
Executive Vice President, Chief of Research and Development Officer
--
--
Ms. Rhonda Heliums
Ms. Rhonda Heliums
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Mr. Iain Gladstone Ross
Mr. Iain Gladstone Ross
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. David Jakob (Dave) Lemus, CPA
Mr. David Jakob (Dave) Lemus, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
收入明细
单位: USD更新时间: 7月6日 周日
单位: USD更新时间: 7月6日 周日
FY2024
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q3
FY2023Q2
FY2023Q1
暂无数据
地区USD
名称
营收
占比
United Kingdom
43.11M
99.67%
Germany
144.00K
0.33%
USA
0.00
0.00%
业务
地区
暂无数据
股东统计
更新时间: 5月17日 周六
更新时间: 5月17日 周六
持股股东
股东类型
持股股东
持股股东
占比
Griffiths (Richard Ian)
24.38%
TCG Crossover Management, LLC
6.42%
Invus Public Equities Advisors, LLC
5.91%
Redmile Group, LLC
4.69%
Morgan Stanley & Co. LLC
4.01%
Other
54.59%
持股股东
持股股东
占比
Griffiths (Richard Ian)
24.38%
TCG Crossover Management, LLC
6.42%
Invus Public Equities Advisors, LLC
5.91%
Redmile Group, LLC
4.69%
Morgan Stanley & Co. LLC
4.01%
Other
54.59%
股东类型
持股股东
占比
Individual Investor
24.38%
Investment Advisor
18.47%
Investment Advisor/Hedge Fund
10.53%
Hedge Fund
7.10%
Research Firm
5.08%
Venture Capital
3.35%
Private Equity
2.43%
Other
28.65%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
130
33.69M
71.34%
-14.09M
2025Q1
133
31.94M
67.63%
-14.00M
2024Q4
128
31.43M
66.56%
-10.23M
2024Q3
111
35.93M
77.05%
-5.19M
2024Q2
96
34.94M
74.95%
-4.57M
2024Q1
86
35.43M
76.18%
+4.14M
2023Q4
61
30.21M
78.15%
-609.51K
2023Q3
58
32.62M
88.08%
+1.55M
2023Q2
54
31.78M
89.08%
+2.79M
2023Q1
52
31.17M
88.54%
+2.74M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Griffiths (Richard Ian)
11.51M
24.38%
+543.58K
+4.95%
Jun 25, 2025
TCG Crossover Management, LLC
3.03M
6.42%
--
--
Mar 31, 2025
Invus Public Equities Advisors, LLC
2.79M
5.91%
-41.94K
-1.48%
Mar 31, 2025
Redmile Group, LLC
2.21M
4.69%
-184.37K
-7.68%
Mar 31, 2025
Morgan Stanley & Co. LLC
1.90M
4.01%
+333.48K
+21.34%
Mar 31, 2025
Lombard Odier Asset Management (USA) Corp.
1.85M
3.92%
-6.29K
-0.34%
Mar 31, 2025
Frazier Life Sciences Management, L.P.
1.15M
2.43%
--
--
Mar 31, 2025
Vivo Capital, LLC
1.11M
2.34%
--
--
Mar 31, 2025
Nantahala Capital Management, LLC
1.04M
2.21%
-7.25K
-0.69%
Mar 31, 2025
Nextech Invest, Ltd.
952.40K
2.02%
--
--
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Virtus LifeSci Biotech Clinical Trials ETF
0.93%
ProShares Ultra Nasdaq Biotechnology
0.03%
Invesco Nasdaq Biotechnology ETF
0.03%
iShares Biotechnology ETF
0.01%
SPDR S&P International Small Cap ETF
0.01%
ActivePassive International Equity ETF
0%
Tema Heart & Health ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
占比0.93%
ProShares Ultra Nasdaq Biotechnology
占比0.03%
Invesco Nasdaq Biotechnology ETF
占比0.03%
iShares Biotechnology ETF
占比0.01%
SPDR S&P International Small Cap ETF
占比0.01%
ActivePassive International Equity ETF
占比0%
Tema Heart & Health ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
